Workflow
Chipscreen(688321)
icon
Search documents
7月17日晚间重要公告一览
Xi Niu Cai Jing· 2025-07-17 10:23
大唐发电:上半年上网电量同比增长1.30% 7月17日晚,大唐发电(601991)发布公告称,截至2025年6月30日,公司及子公司累计完成上网电量约 1239.93亿千瓦时,同比上升1.30%。其中,风电和光伏上网电量同比分别增长31.27%和36.35%。 资料显示,大唐发电成立于1994年12月,主营业务是以火电为主的发电。 所属行业:公用事业–电力–火力发电 所属行业:有色金属–小金属–钼 微芯生物:上半年净利润预增35% 7月17日晚,微芯生物(688321)发布2025年上半年业绩预告,公司预计上半年实现营业收入4.07亿 元,同比增长35%;预计实现归属于母公司所有者的净利润约3006万元,同比增加173%,同比扭亏为 盈。 资料显示,微芯生物成立于2001年3月,主营业务是药物技术开发、相关成果商业应用。 7月17日晚,北自科技(603082)发布公告称,公司与巨石集团淮安有限公司签订了《设备采购合 同》,合同总金额为1.64亿元。 资料显示,北自科技成立于2002年10月,主营业务是智能物流系统和装备的研发、设计、制造与集成业 务。 所属行业:机械设备–自动化设备–其他自动化设备 金钼股份: ...
微芯生物: 关于2025年半年度业绩预告的自愿性披露公告
Zheng Quan Zhi Xing· 2025-07-17 09:17
(一)业绩预告期间 证券代码:688321 证券简称:微芯生物 公告编号:2025-043 深圳微芯生物科技股份有限公司 关于 2025 年半年度业绩预告的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 二、上年同期业绩情况 公司 2024 年半年度营业收入为 30,216.05 万元,归属于母公司所有者的净利 润为-4,100.64 万元,扣除非经常性损益后归属母公司所有者的净利润为-4,717.82 万元。 三、本期业绩变化的主要原因 本报告期内,公司产品西达本胺弥漫大 B 细胞淋巴瘤适应症新进医保,西 格列他钠销售策略优化且"糖肝共管"独特优势得到市场认可,因此两款产品销 量大幅增长。2025 年第二季度公司营收预计同比增长 43%,环比增长 51%,归 属母公司所有者的净利润实现扭亏。 四、风险提示以及其他说明事项 (二)业绩预告情况 经公司财务部门初步测算: 相比,将增加 10,512.95 万元,同比增加 35%。 较上年同期数据相比,将增加 7,106.64 万元,同比增 ...
微芯生物(688321) - 2025 Q2 - 季度业绩预告
2025-07-17 08:15
[Chipscreen Biosciences 2025 Semi-Annual Performance Forecast](index=1&type=section&id=Voluntary%20Disclosure%20Announcement%20by%20Shenzhen%20Chipscreen%20Biosciences%20Co.%2C%20Ltd.%20Regarding%20its%202025%20Semi-Annual%20Performance%20Forecast) The company expects significant growth and a turnaround to profitability in H1 2025, with revenue projected to increase by 35% to approximately RMB 407.29 million, and net profit attributable to shareholders by 173% to approximately RMB 30.06 million [Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company anticipates substantial year-on-year growth and a return to profitability for its key financial metrics in the first half of 2025 [Performance Forecast Period](index=1&type=section&id=(I)%20Performance%20Forecast%20Period) This performance forecast covers the period from January 1, 2025, to June 30, 2025 - The statistical period for this performance forecast is from January 1, 2025, to June 30, 2025[2](index=2&type=chunk) [Performance Forecast Details](index=1&type=section&id=(II)%20Performance%20Forecast%20Details) Preliminary calculations indicate significant year-on-year growth across revenue, net profit, and non-recurring net profit, with both profit metrics achieving a turnaround to profitability 2025 Semi-Annual Performance Forecast Key Data | Indicator | 2025 Semi-Annual Estimate | Year-on-Year Growth | | :--- | :--- | :--- | | Operating Revenue | Approx. RMB 407.29 million | 35% | | Net Profit Attributable to Shareholders | Approx. RMB 30.06 million | 173% | | Non-Recurring Net Profit Attributable to Shareholders | Approx. RMB 21.19 million | 145% | [Unaudited Performance Forecast](index=1&type=section&id=(III)%20Unaudited%20Performance%20Forecast) The performance forecast data presented is a preliminary calculation by the company's finance department and has not yet been audited by a certified public accountant - This performance forecast data has not been audited by a certified public accountant[4](index=4&type=chunk) [Prior Period Performance Review](index=1&type=section&id=II.%20Prior%20Period%20Performance%20Review) In H1 2024, the company reported RMB 302.16 million in operating revenue, with net profit and non-recurring net profit both in a loss state, providing a baseline for current period improvements 2024 Semi-Annual Performance Data | Indicator | 2024 Semi-Annual | | :--- | :--- | | Operating Revenue | RMB 302.16 million | | Net Profit Attributable to Shareholders | -RMB 41.01 million | | Non-Recurring Net Profit Attributable to Shareholders | -RMB 47.18 million | [Primary Reasons for Performance Change](index=2&type=section&id=III.%20Primary%20Reasons%20for%20Performance%20Change) The strong performance growth is primarily driven by increased sales of two core products, Chidamide and Seglitaz, with the company achieving profitability in Q2 2025 - Core product sales growth is the main driver of performance improvement - **Chidamide**: New indication for diffuse large B-cell lymphoma included in the national medical insurance catalog - **Seglitaz**: Optimized sales strategy, with its unique "diabetes and liver co-management" advantage gaining market recognition[6](index=6&type=chunk) - Q2 2025 performance was strong, with revenue expected to grow by **43% year-on-year** and **51% quarter-on-quarter**, and net profit attributable to shareholders achieving a turnaround to profitability[6](index=6&type=chunk) [Risk Warning and Other Disclosures](index=2&type=section&id=IV.%20Risk%20Warning%20and%20Other%20Disclosures) The company confirms no significant uncertainties affecting the forecast's accuracy but reminds investors that the data is preliminary and subject to the final semi-annual report - The company states that no significant uncertainties affecting the accuracy of this performance forecast have been identified[7](index=7&type=chunk) - Investors are advised that the current forecast data is preliminary, and the specific financial data will be subject to the company's officially disclosed 2025 semi-annual report[7](index=7&type=chunk)
微芯生物:预计2025年上半年净利润同比增长173%
news flash· 2025-07-17 08:05
微芯生物公告,预计2025年半年度实现营业收入约为4.07亿元,同比增加35%;预计2025年半年度实现 归属于母公司所有者的净利润约为3006万元,同比增加173%;预计2025年半年度实现扣除非经常性损 益后归属母公司所有者的净利润约为2119万元,同比增加145%。本报告期内,公司产品西达本胺弥漫 大B细胞淋巴瘤适应症新进医保,西格列他钠销售策略优化且"糖肝共管"独特优势得到市场认可,因此 两款产品销量大幅增长。2025年第二季度公司营收预计同比增长43%,环比增长51%,归属母公司所有 者的净利润实现扭亏。 ...
肝炎概念涨2.17%,主力资金净流入这些股
截至7月16日收盘,肝炎概念上涨2.17%,位居概念板块涨幅第7,板块内,120股上涨,润都股份、万 邦德、力生制药等涨停,广生堂、福瑞股份、莱美药业等涨幅居前,分别上涨16.55%、9.55%、 8.48%。跌幅居前的有之江生物、*ST苏吴、微芯生物等,分别下跌6.08%、5.02%、2.71%。 今日涨跌幅居前的概念板块 | 603882 | 金域医 | 0.34 | 2.48 | 1840.31 | 5.55 | | --- | --- | --- | --- | --- | --- | | | 学 | | | | | | 002038 | 双鹭药 | 2.00 | 2.59 | 1834.82 | 10.96 | | | 业 | | | | | | 000766 | 通化金 马 | 1.29 | 2.13 | 1802.62 | 3.62 | | 300233 | 金城医 药 | 4.28 | 9.32 | 1763.81 | 2.97 | | 688321 | 微芯生 物 | -2.71 | 4.66 | 1763.67 | 2.69 | | 300194 | 福安药 业 | 2.95 | 5.29 ...
54只科创板股获融资净买入超1000万元
科创板融资余额环比前一日增加3456.88万元,其中,54股融资余额环比增加超1000万元,融资净买入 居前的有生益电子、澜起科技、中控技术等股。 证券时报·数据宝统计显示,截至7月15日,科创板两融余额合计1601.25亿元,较上一交易日增加 4295.86万元,其中,融资余额合计1595.30亿元,较上一交易日增加3456.88万元。 科创板股中,最新融资余额超亿元的有425只,其中,融资余额在10亿元以上的有17只,融资余额在 5000万元至1亿元的有112只,融资余额低于5000万元的有48只。 | 688068 | 热景生 | 28076.50 | 3113.34 | 12.47 | 4.42 | | --- | --- | --- | --- | --- | --- | | | 物 | | | | | | 688063 | 派能科 | 65672.79 | 3052.06 | 4.87 | -3.80 | | | 技 | | | | | | 688486 | 龙迅股 份 | 14614.71 | 2885.26 | 24.60 | 3.45 | | 688799 | 华纳药 厂 | 29009.9 ...
科创医药ETF嘉实(588700)近2周新增规模同类第一!机构:创新药出海趋势将长期持续
Sou Hu Cai Jing· 2025-07-10 05:50
Group 1 - The core viewpoint highlights the significant growth and performance of the Kexin Pharmaceutical ETF managed by Jiashi, with a notable increase in trading volume and fund size [2] - As of July 9, the Kexin Pharmaceutical ETF achieved a daily average trading volume of 34.95 million yuan over the past month, ranking first among comparable funds [2] - The fund's size increased by 16.76 million yuan in the past two weeks, also ranking first among comparable funds [2] - The ETF saw a total inflow of 12.84 million yuan over the last ten trading days, indicating strong investor interest [2] - The net value of the Kexin Pharmaceutical ETF rose by 36.83% over the past year, showcasing its strong performance [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [2][4] - On July 9, Shanghai Pharmaceuticals announced an expected net profit of 4.45 billion yuan for the first half of 2025, representing a year-on-year increase of approximately 52% [4] Group 3 - Short-term market expectations for overseas transactions in innovative drugs are high, leading to a continuous rise in valuations [5] - China's innovative drug research and development capabilities are competitive globally, and the trend of innovative drugs going overseas is expected to persist [5] - The commercial health insurance sector in China is anticipated to see significant growth in premium income and payout rates, becoming an important source of funding for innovative drugs [5]
创新药三期临床告捷!微芯生物仍增收不增利
Core Viewpoint - MicuBio (688321.SH) announced the final top-line analysis data from its pivotal Phase III clinical trial (DEB study) for its self-developed drug, Sidanbamide, which significantly outperformed the control group in terms of event-free survival (EFS), achieving the primary endpoint of the study [2][4] Group 1: Product and Market Information - Sidanbamide is the world's first subtype-selective histone deacetylase (HDAC) inhibitor and belongs to the class of epigenetic regulators [4] - The drug received conditional approval for DLBCL indications from the National Medical Products Administration (NMPA) in April 2024 and is set to be included in the national medical insurance catalog by the end of 2024, making it the only oral innovative drug for first-line DLBCL within the insurance coverage [4] - DLBCL is the most common type of lymphoma in China, with approximately 60,000 to 80,000 new cases reported annually, and the incidence rate is gradually increasing [4] Group 2: Clinical Trial and Regulatory Information - The company previously received conditional approval based on interim analysis data, requiring completion of clinical trials within two years to obtain complete clinical data [4] - The announcement of the final results signifies an expansion of the existing indication range for the product, positively impacting the company [4] - Conditional approval allows for accelerated market entry of urgently needed drugs with significant clinical value, even before completing full clinical research [5] Group 3: Competitive Landscape - The treatment field for DLBCL has seen recent breakthroughs, including the approval of Tafasitamab, a CD19 monoclonal antibody for relapsed/refractory DLBCL, which does not directly compete with Sidanbamide as it is used for second-line or later treatments [5] Group 4: Financial Performance - The company reported a revenue of 658 million yuan for 2024, a year-on-year increase of 25.63%, but faced a net loss of 115 million yuan, a significant decline of 228.97% [6] - In the first quarter of 2025, revenue was 162 million yuan, up 24.24% year-on-year, but the net loss was 19 million yuan, a decrease of 4.64% compared to the previous year [6]
创新药牛股大消息
Zhong Guo Ji Jin Bao· 2025-07-09 12:08
【导读】微芯生物自主研发的西达本胺相关Ⅲ期临床试验,获得最终结果的顶线分析数据 近期股价翻倍的创新药牛股又有大消息。 微芯生物7月9日下午公告称,公司自主研发的西达本胺针对一线治疗弥漫大B细胞淋巴瘤(DLBCL)关键性Ⅲ期临床试验(DEB研究),已于近日获得最 终结果的顶线分析数据,试验组无事件生存期(EFS)显著优于对照组,达成研究主要终点。 自5月28日至今,微芯生物股价震荡上涨,最高涨幅达103%。 7月9日,微芯生物股价以31.3元/股报收,最新市值为128亿元。 西达本胺是国家863及"重大新药创制"专项成果,是微芯生物独家发现的全新机制新分子实体药物,是全球首个亚型选择性组蛋白去乙酰化酶(HDAC) 抑制剂。 而且,西达本胺是中国首个授权美国等发达国家专利的原创新药,开创了中国创新药对欧美进行专利授权(license-out)的先河。 2006年,微芯生物与沪亚生物达成西达本胺海外多个地区的专利授权。 2013年,微芯生物将西达本胺在中国台湾地区的权利授权给华上生技。目前,西达本胺已在日本、中国台湾获批多项适应症。 2024年4月,基于DEB研究期中分析综合数据结果,西达本胺联合R-CHOP用于M ...
创新药牛股大消息
中国基金报· 2025-07-09 11:44
【导读】微芯生物自主研发的西达本胺相关Ⅲ期临床试验,获得最终结果的顶线分析数据 中国基金报记者 卢鸰 近期股价翻倍的创新药牛股又有大消息。 自5月28日至今,微芯生物股价震荡上涨,最高涨幅达103%。 7月9日,微芯生物股价以31.3元/股报收,最新市值为128亿元。 西达本胺是国家863及"重大新药创制"专项成果,是微芯生物独家发现的全新机制新分子实体 药物,是全球首个亚型选择性组蛋白去乙酰化酶(HDAC)抑制剂。 而且,西达本胺是中国首个授权美国等发达国家专利的原创新药,开创了中国创新药对欧美 进行专利授权(license-out)的先河。 2006年,微芯生物与沪亚生物达成西达本胺海外多个地区的专利授权。 2013年,微芯生物将西达本胺在中国台湾地区的权利授权给华上生技。目前,西达本胺已在 日本、中国台湾获批多项适应症。 2024年4月,基于DEB研究期中分析综合数据结果,西达本胺联合R-CHOP用于MYC和 BCL2表达阳性的既往未经治疗的DLBCL适应症获得国家药品监督管理局附条件批准。 微芯生物7月9日下午公告称,公司自主研发的西达本胺针对一线治疗弥漫大B细胞淋巴瘤 (DLBCL)关键性Ⅲ期临床试 ...